Clinical effect on the treatment of the low-middle frequency sudden hearing loss with postaurical injection of methylprednisolone.
- Author:
Sien WU
;
Qingming LI
;
Suhong HUANG
- Publication Type:Journal Article
- MeSH:
Alprostadil;
therapeutic use;
Biological Products;
therapeutic use;
Glucocorticoids;
administration & dosage;
therapeutic use;
Hearing Loss, Sensorineural;
Hearing Loss, Sudden;
drug therapy;
Humans;
Injections;
Methylprednisolone;
administration & dosage;
therapeutic use;
Prednisone;
administration & dosage;
therapeutic use;
Treatment Outcome
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2015;29(10):928-930
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinical efficacy on the treatment of the low-middle frequency sudden hearing loss with postaurical injection of methylprednisolone.
METHOD:The 80 cases of the low-middle frequency sudden hearing loss were randomly divided into postaurical injection and oral hormone groups. The postaurical injection group (42 cases) received the postaurical injection of methylprednisolone, 40 mg/2 d, combined with the treatment of Ginkgo dipyidamolum and Alprostadil for 14 d; The oral hormone group (38 cases) received the oral prednisone, 1 mg/kg/d, administrated once on the morning for 3 d, if effective, prolonging for another 2 d, as mentioned above for Ginkgo dipyidamolum and Alprostadil.
RESULT:The total effective rate was 88.10% in postaurical injection group and 86. 4o%in oral hormone group. There was no significant difference between the twbogroups( P> 0. 5).
CONCLUSION:Postaurical injection of methylprednisolone for the low-middle frequency sudden hearing loss is effective, safe and simple, which may be an alternative for systemic administration of gulcocorticoid.
